Trial Profile
Expanded Access Information for Physicians for Bamlanivimab (LY3819253) Emergency Investigational New Drug [EIND]
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 26 Nov 2020
Price :
$35
*
At a glance
- Drugs Bamlanivimab (Primary)
- Indications COVID 2019 infections
- Focus Expanded access; Therapeutic Use
- Sponsors Eli Lilly and Company
- 19 Nov 2020 Status changed from recruiting to completed.
- 28 Oct 2020 New trial record